Peptides for Disease Research

We’re rapidly producing custom peptides and peptide libraries for the major proteins of SARS-COV-2. With high quality products available fast for researchers combating Covid19, come and see Mimotopes for all of your peptide needs.

Custom Peptide Libraries

The advantage of our proprietary parallel synthesis technology is that Mimotopes can synthesise hundreds of peptides simultaneously, and thus greatly reduce the price and time to delivery.

High quality Peptide Libraries affordable prices

30 Years Experience

Mimotopes is the founder of peptide library technology. We have only continued to grow and learn over the decades – now our expertise is unrivaled.

We work tirelessly to stay ahead of the game to ensure, as always, that we supply the best possible products, including SARS-CoV-2 peptides.

Efficient & Economical Screening Solutions

PepsetTM PeptideLibraries have dozens of potential applications. With applications in covid19 vaccine and drug development, disease screening, and epitope mapping, a peptide library can be exclusively designed to your specifications, for your research. 

  • Discover crucial residues with an Alanine Scan Library
  • Map epitopes with an Overlapping Library
  • Narrow down the shortest active sequences with a Truncated Library

Dozens of Options to Customise

A standard PepSetTM Peptide Library can be supplied as with a precise length and offset designed to best suit your assays, but that’s not all. Modifications and labels can be applied to the termini or even within the sequence. Arrange a consultation to discuss your options and design your library.

Contact us today for a peptide quote! 

Australia

☎ +61 3 9565 1111

✉ australia@mimotopes.com

North and South America 

☎ +1 651 603 0909

 useast@mimotopes.com

asia

☎ +61 3 9565 1111

✉ asia@mimotopes.com


UK / Europe / Africa / Middle East

☎ +44 (0)151 556 0547

✉ europe@mimotopes.com

Contact us today for a peptide quote! 

Australia

☎ +61 3 9565 1111

australia@mimotopes.com

North and South America 

☎ +1 651 603 0909

  ✉ useast@mimotopes.com 
  ✉ uswest@mimotopes.com

asia

☎ +61 3 9565 1111

✉ asia@mimotopes.com

UK/ Europe/ Africa/ Middle East

☎ +44 (0)151 556 0547

✉ europe@mimotopes.com

Go to article: Home | What Rishi Sunak can do for the UK pharma industry Go to article: In this issueGo to article: ContentsGo to article: CSafeGo to article: TripletreeGo to article: BriefingGo to article: Industry newsGo to article: The pharma industry briefingGo to article: BEA TechnologiesGo to article: Mimotopes Company Insight Go to article: MimotopesGo to article: CommentGo to article: GSK speeds up the race to market first RSV vaccine for older adultsGo to article: Biden’s directive on foreign biotech investments impacts manufacturersGo to article: Novo Nordisk targets FDA approval for once-weekly insulin after Phase III dataGo to article: ‘Twindemic’ risks warrant immediate steps in Europe and the US Go to article: A game of two halves for Roche’s recently approved wet AMD assetsGo to article: Dr. Paul LohmannGo to article: NiproGo to article: In DepthGo to article: What Rishi Sunak can do for the UK pharma industryGo to article: Inside the European mass shift to data-driven health solutionsGo to article: Chronic drug shortages signal difficult outlook for cardiovascular careGo to article: Can gene therapies for haemophilia defend their high price tags?Go to article: Trial termination analysis unveils a silver lining for patient recruitmentGo to article: New dawn for the EU's joint procurement crisis responseGo to article: SkyepharmaGo to article: Bio Image Systems Inc.Go to article: In DataGo to article: The pharma industry found it easier to fill AI vacancies in Q3 2022 Go to article: Internet of things hiring levels in the pharma dropped in October 2022Go to article: Artificial intelligence hiring levels in the pharma dropped in October 2022Go to article: BaxterGo to article: EventsGo to article: Next issue